AUSTIN, Texas, Feb. 22, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received medical device licenses from Health Canada's Therapeutic Products Directorate, Medical Devices Bureau for the ARIES® System and ARIES® HSV 1&2 Assay. The ARIES® System and HSV 1&2 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market.
"We are excited to receive medical device licenses for the ARIES® System and the ARIES® HSV 1&2 Assay in Canada. We look forward to rapidly launching this revolutionary system there," said Todd Bennett, VP, Global Sales and Customer Operations, Luminex Corporation. "We are confident that the ARIES® System will answer many of our Canadian clinical laboratory customers' needs by increasing efficiency, reducing errors, and delivering accurate and timely data to improve patient care."
About the ARIES® System The ARIES® System is a sample to answer system designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory environment. The ARIES® System uses internal barcode scanning and other advanced features to minimize operator errors. The system contains two independent modules that support from one to six cassettes each, allowing for both STAT and Batch testing. IVD and MultiCode® Analyte Specific Reagents can be run simultaneously with a common Universal Assay Protocol. An integrated touchscreen PC eliminates the need for a separate computer, stand-alone keyboard, and mouse, thus maximizing valuable bench space. The ARIES® System is the most powerful and intuitive of any sample to answer solution and provides control of the testing process, from accession of the sample to results reporting.
About Herpes Simplex Virus 1 and 2 (HSV-1 and 2) HSV-1 is a contagious infection, which is common and endemic throughout the world. The virus causes lifelong infection, and there is no cure, although treatment can reduce symptoms. It is mainly transmitted through oral-oral contact and causes "cold sores." HSV-2 infection is widespread and mainly sexually transmitted. It is estimated that up to 20 million people are newly infected with HSV-2 each year. HSV-2 causes genital herpes, characterized by the occasional appearance of painful genital ulcers. Prescription antivirals to treat herpes simplex include acyclovir, famciclovir, and valacyclovir. Serious complications occur most often in unborn babies, newborns, and people who have a long-term illness such as cancer or HIV/AIDS, or have a weakened immune system.
To learn more or request a demo, visit: http://www.luminexcorp.com/ARIES
About Luminex Corporation Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology, and life science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research, and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward- looking statements in this release include statements regarding the available market for ARIES® and related assays, future revenue growth anticipated for ARIES® and related assays, and the development, testing and regulatory approval progress of our pipeline products, including ARIES® related assays. The words "believe", "expect", "intend", "anticipates", "confident", "will", "could", "should", and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, our ability to launch products on time, the timing of regulatory approvals, the outcome of clinical trials as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Contacts: Luminex Investor Contact Harriss Currie, 512.219.8020 Sr. Vice President of Finance and CFO email@example.com
Luminex Media Contact Christine Valle, 512.219.8020 Sr. Manager, Global Marketing firstname.lastname@example.org
SOURCE Luminex Corporation